Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of ...

Actinium Pharmaceuticals (ATNM) announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M ...

Pharma brands that fail to evolve risk losing relevance in a world where patients demand more control, transparency, and ...

The Global Market for Micro Bioreactor System was estimated to be worth USD 134.7 Million in 2023 and is forecast to a readjusted size of USD 276.7 Million by 2030 with a CAGR of 10.7% during the ...

DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...

UBS on Monday said frequently "ill-informed" public debate about potential risks from its business activities and size has ...

Automaker Stellantis is investing 38 million euros ($41 million) in its Verrone plant in Northern Italy to manufacture parts ...

FRANKFURT (Reuters) -German pharma firm Stada plans to launch its initial public offering (IPO) as soon as Wednesday, two ...

Some investors fear Reckitt may be forced to raise its prices in the US, or face higher costs, due to its low manufacturing ...

Acquisition further builds on Clario's neuroscience expertise and capabilities PHILADELPHIA, March 17, 2025 /PRNewswire/ -- Clario, a leading provider of endpoint data solutions to the ...

Asana's 2024 results showed mixed performance, with 11% sales growth and positive free cash flow. See why I rate ASAN stock a ...

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...